483
Sciegen Pharmaceuticals IncFDA 483 - Sciegen Pharmaceuticals Inc - April 17, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of ScieGen Pharmaceuticals Inc., an analytical laboratory in Hauppauge, NY, identified one observation. The firm was cited for failing to retain appropriate reserve samples for reference products used in an in vitro comparative dissolution study. This indicates a deficiency in their sample retention practices.
Open in Dashboard
ID · e2f9042a-4ff1-46f0-bbb2-f2cb753419c1